EP4125837A4 - USE OF COMBINATIONS OF BUPROPION AND DEXTROMETHORPHAN FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - Google Patents
USE OF COMBINATIONS OF BUPROPION AND DEXTROMETHORPHAN FOR THE TREATMENT OF NEUROLOGICAL DISORDERS Download PDFInfo
- Publication number
- EP4125837A4 EP4125837A4 EP21779322.3A EP21779322A EP4125837A4 EP 4125837 A4 EP4125837 A4 EP 4125837A4 EP 21779322 A EP21779322 A EP 21779322A EP 4125837 A4 EP4125837 A4 EP 4125837A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- dextromethorphane
- bupropion
- combinations
- neurological diseases
- treat neurological
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063002132P | 2020-03-30 | 2020-03-30 | |
| US202063016178P | 2020-04-27 | 2020-04-27 | |
| US202063032517P | 2020-05-29 | 2020-05-29 | |
| US202063032567P | 2020-05-30 | 2020-05-30 | |
| US16/894,713 US10898453B2 (en) | 2013-11-05 | 2020-06-05 | Bupropion as a modulator of drug activity |
| PCT/US2021/024718 WO2021202419A1 (en) | 2020-03-30 | 2021-03-29 | Use of bupropion and dextromethorphan combinations for treating neurological disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4125837A1 EP4125837A1 (en) | 2023-02-08 |
| EP4125837A4 true EP4125837A4 (en) | 2024-03-20 |
Family
ID=77930161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP21779322.3A Pending EP4125837A4 (en) | 2020-03-30 | 2021-03-29 | USE OF COMBINATIONS OF BUPROPION AND DEXTROMETHORPHAN FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4125837A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7637150B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220161414A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115697314A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3179048A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021202419A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12194006B2 (en) | 2013-11-05 | 2025-01-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11433067B2 (en) | 2013-11-05 | 2022-09-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12109178B2 (en) | 2013-11-05 | 2024-10-08 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11969421B2 (en) | 2013-11-05 | 2024-04-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11534414B2 (en) | 2013-11-05 | 2022-12-27 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12569479B2 (en) | 2016-05-25 | 2026-03-10 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12472156B2 (en) | 2020-06-05 | 2025-11-18 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| US20250073188A1 (en) | 2020-06-05 | 2025-03-06 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| US12433884B2 (en) | 2020-06-05 | 2025-10-07 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| CN122440635A (zh) | 2020-12-01 | 2026-07-24 | 安泰赛普生物风投二代有限责任公司 | 用于降低抑郁症患者的自杀风险的安非他酮和右美沙芬 |
| CA3227072A1 (en) * | 2021-07-21 | 2023-01-26 | Antecip Bioventures Ii Llc | Treatment of depression |
| JP2025517368A (ja) * | 2022-05-17 | 2025-06-05 | アンテシップ バイオベンチャーズ トゥー エルエルシー | うつ病の治療 |
| US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
| US12036191B1 (en) | 2022-06-30 | 2024-07-16 | Antecip Bioventures Ii Llc | Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan |
| US12156914B2 (en) | 2022-06-30 | 2024-12-03 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising bupropion and cysteine |
| US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
| US12194036B2 (en) | 2022-07-07 | 2025-01-14 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| US11844797B1 (en) | 2023-04-20 | 2023-12-19 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| KR20250114110A (ko) * | 2022-11-28 | 2025-07-28 | 안테씨프 바이오벤쳐스 투 엘엘씨 | 약물 활성의 조절제로서의 부프로피온 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10080727B2 (en) * | 2013-11-05 | 2018-09-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US20200215059A1 (en) * | 2013-11-05 | 2020-07-09 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US20210052521A1 (en) * | 2013-11-05 | 2021-02-25 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US20210077428A1 (en) * | 2013-11-05 | 2021-03-18 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3981403A1 (en) * | 2013-11-05 | 2022-04-13 | Antecip Bioventures II LLC | Compositions and methods comprising bupropion or related compounds and dextromethorphan |
| US9763932B2 (en) * | 2013-11-05 | 2017-09-19 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US10898453B2 (en) * | 2013-11-05 | 2021-01-26 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
-
2021
- 2021-03-29 CN CN202180038675.3A patent/CN115697314A/zh active Pending
- 2021-03-29 EP EP21779322.3A patent/EP4125837A4/en active Pending
- 2021-03-29 KR KR1020227037493A patent/KR20220161414A/ko active Pending
- 2021-03-29 JP JP2022559518A patent/JP7637150B2/ja active Active
- 2021-03-29 CA CA3179048A patent/CA3179048A1/en active Pending
- 2021-03-29 WO PCT/US2021/024718 patent/WO2021202419A1/en not_active Ceased
-
2024
- 2024-12-06 JP JP2024212992A patent/JP7890382B2/ja active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10080727B2 (en) * | 2013-11-05 | 2018-09-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US20200215059A1 (en) * | 2013-11-05 | 2020-07-09 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US20210052521A1 (en) * | 2013-11-05 | 2021-02-25 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US20210077428A1 (en) * | 2013-11-05 | 2021-03-18 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO2021202419A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023519965A (ja) | 2023-05-15 |
| CA3179048A1 (en) | 2021-10-07 |
| KR20220161414A (ko) | 2022-12-06 |
| WO2021202419A1 (en) | 2021-10-07 |
| JP7637150B2 (ja) | 2025-02-27 |
| CN115697314A (zh) | 2023-02-03 |
| JP2025032232A (ja) | 2025-03-11 |
| EP4125837A1 (en) | 2023-02-08 |
| JP7890382B2 (ja) | 2026-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3976010A4 (en) | Oligonucleotides and methods of use for treating neurological diseases | |
| EP4226924A4 (en) | USE OF PENEHYCLIDINE IN THE TREATMENT OR PREVENTION OF EYE DISEASES IMPAIRING VISION | |
| EP3900717C0 (en) | VIDOFLUDIMUS FOR USE IN THE TREATMENT OR PREVENTION OF VIRAL DISEASES | |
| EP4117659A4 (en) | Methods of treating respiratory disease with deupirfenidone | |
| EP4122474A4 (en) | Use of mitochondria for treatment and/or prevention of tendon damage or related diseases | |
| EP4153168A4 (en) | Use of terpenoids in the treatment or prevention of fibrotic diseases | |
| EP4352231A4 (en) | TREATMENT OF DISEASES ASSOCIATED WITH ANGPTL4 | |
| EP4447973A4 (en) | USE OF POLYTHERAPY FOR CANCER TREATMENT | |
| EP4188410A4 (en) | CHIMERIC PROTEINS AND METHODS OF USE FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | |
| EP4514347A4 (en) | TREATMENT OF NEUROLOGICAL DISORDERS | |
| EP4216962A4 (en) | Line-1 inhibitors to treat disease | |
| EP4338267A4 (en) | Variants of sirt6 for use in preventing and/or treating age-related diseases | |
| EP4413032A4 (en) | TREATMENT OF MAST CELL DISORDERS | |
| EP4370153A4 (en) | Methods of treating neurological diseases | |
| EP4210755A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF NEUROLOGICAL DISORDERS | |
| EP4185319A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISEASES | |
| EP4514357A4 (en) | METHODS OF TREATING NEUROLOGICAL DISORDERS | |
| EP4363056A4 (en) | Use of terpenoids in the treatment or prevention of fibrotic diseases | |
| EP3943110C0 (en) | USE OF PHOTOSENSITIZERS FOR THE TREATMENT OF RESPIRATORY VIRAL INFECTIONS | |
| EP4398908A4 (en) | TREATMENT OF NEUROLOGICAL DISORDERS | |
| EP4410296A4 (en) | DIRECT TRANSDIFFERENTIATION FOR THE TREATMENT OF NEUROLOGICAL DISEASES | |
| EP4469156A4 (en) | COMPOSITIONS FOR THE TREATMENT OF A NEUROLOGICAL DISEASE | |
| EP4046658A4 (en) | APPLICATIONS OF IGF1R-FREE BINDING SUBSTANCE IN THE PREVENTION AND/OR TREATMENT OF INFLAMMATORY DISEASES | |
| EP4267163A4 (en) | COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS | |
| EP4132540A4 (en) | BISPECIFIC APTAMER COMPOSITIONS FOR THE TREATMENT OF RETINAL DISORDERS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20221028 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230509 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40082817 Country of ref document: HK |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20240220 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/34 20060101ALI20240214BHEP Ipc: A61P 25/24 20060101ALI20240214BHEP Ipc: A61K 31/485 20060101ALI20240214BHEP Ipc: A61K 31/137 20060101AFI20240214BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20250226 |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: TABUTEAU, HERRIOT |